UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term follow-up of psilocybin-facilitated smoking cessation

The American journal of drug and alcohol abuse, 2017-01, Vol.43 (1), p.55-60

2017

Volltextzugriff (PDF)

Is good science leading the way in the therapeutic use of psychedelic drugs?

Psychological medicine, 2022-10, Vol.52 (14), p.2849-2851

2022

Volltextzugriff (PDF)

Why was early therapeutic research on psychedelic drugs abandoned?

Psychological medicine, 2022-01, Vol.52 (1), p.26-31

Hall, Wayne

2022

Volltextzugriff (PDF)

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

The American journal of drug and alcohol abuse, 2019-03, Vol.45 (2), p.161-169

2019

Volltextzugriff (PDF)

It is not and never has been just about the drug: The need to emphasise psychotherapy in psychedelic‐assisted psychotherapy

International journal of mental health nursing, 2023-06, Vol.32 (3), p.945-946

2023

Volltextzugriff (PDF)

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

The International journal of drug policy, 2021-12, Vol.98, p.103380-103380, Article 103380

2021

Volltextzugriff (PDF)

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

The International journal of drug policy, 2022-02, Vol.100, p.103518-103518, Article 103518

2022

Volltextzugriff (PDF)

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

British journal of psychiatry, 2012-03, Vol.200 (3), p.238-244

2012

Volltextzugriff (PDF)

Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis

Psychology of addictive behaviors, 2024-02, Vol.38 (1), p.101-113

2024

Volltextzugriff (PDF)

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

The American journal of drug and alcohol abuse, 2018-01, Vol.44 (1), p.24-36

2018

Volltextzugriff (PDF)

Use of marijuana exclusively for medical purposes

Drug and alcohol dependence, 2019-02, Vol.195, p.13-15

2019

Volltextzugriff (PDF)

Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis

International journal of mental health nursing, 2023-08, Vol.32 (4), p.1025-1037

2023

Volltextzugriff (PDF)

Alleviation of Opioid Withdrawal by Cannabis and Delta-9-Tetrahydrocannabinol: A Systematic Review of Observational and Experimental Human Studies

Drug and alcohol dependence, 2022-12, Vol.241, p.109702-109702, Article 109702

2022

Volltextzugriff (PDF)

The influence of parent and peer disapproval on youth marijuana use mediated by youth risk perception: Focusing on the state comparison

Drug and alcohol dependence, 2022-11, Vol.240, p.109641, Article 109641

2022

Volltextzugriff (PDF)

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

The American journal of drug and alcohol abuse, 2018-01, Vol.44 (1), p.37-46

2018

Volltextzugriff (PDF)

Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial

Drug and alcohol dependence, 2022-05, Vol.234, p.109388-109388, Article 109388

2022

Volltextzugriff (PDF)

Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts

The American journal of drug and alcohol abuse, 2023-09, Vol.49 (5), p.541-545

2023

Volltextzugriff (PDF)

Quetiapine treatment for cannabis use disorder

Drug and alcohol dependence, 2021-01, Vol.218, p.108366-108366, Article 108366

2021

Volltextzugriff (PDF)

The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice

Journal of midwifery & women's health, 2022-05, Vol.67 (3), p.373-383

2022

Volltextzugriff (PDF)

Cannabis use for pain relief in the context of health service barriers: Accounts of street‐involved Nigerian women suffering chronic pain

Drug and alcohol review, 2023-02, Vol.42 (2), p.309-317

2023

Volltextzugriff (PDF)

Young adult opioid misuse indicates a general tendency toward substance use and is strongly predicted by general substance use risk

Drug and alcohol dependence, 2022-06, Vol.235, p.109442-109442, Article 109442

2022

Volltextzugriff (PDF)

Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion

Healthcare Policy | Politiques de Santé, 2023-05, Vol.18 (4), p.134-142

2023

Volltextzugriff (PDF)

Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities

Healthcare Policy | Politiques de Santé, 2023-05, Vol.18 (4), p.143-148

2023

Volltextzugriff (PDF)

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico

The American journal of drug and alcohol abuse, 2023-09, Vol.49 (5), p.587-596

2023

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Aktive Filter

KollektionApplied Social Sciences Index & Abstracts (ASSIA)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(66)

Sprache

Englisch
(66)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term follow-up of psilocybin-facilitated smoking cessation

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Is good science leading the way in the therapeutic use of psychedelic drugs?

Why was early therapeutic research on psychedelic drugs abandoned?

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

It is not and never has been just about the drug: The need to emphasise psychotherapy in psychedelic‐assisted psychotherapy

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Use of marijuana exclusively for medical purposes

Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis

Alleviation of Opioid Withdrawal by Cannabis and Delta-9-Tetrahydrocannabinol: A Systematic Review of Observational and Experimental Human Studies

The influence of parent and peer disapproval on youth marijuana use mediated by youth risk perception: Focusing on the state comparison

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial

Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts

Quetiapine treatment for cannabis use disorder

The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice

Cannabis use for pain relief in the context of health service barriers: Accounts of street‐involved Nigerian women suffering chronic pain

Young adult opioid misuse indicates a general tendency toward substance use and is strongly predicted by general substance use risk

Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion

Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico

Aktive Filter

Suchergebnisse filtern